Fig. S5.

WT161 with BTZ induces significant cytotoxicity in patient tumor cells but not in normal PBMCs. (A and B) Primary tumor cells from MM patients were treated with BTZ at the indicated concentrations in the absence or presence of WT161 or tubacin for 24 h. A indicates the comparison of WT161 vs. Tubacin (fixed concentration) in the presence of BTZ (one dose), whereas B shows the combination of WT161 with BTZ at different concentrations. Moreover, these MM tumor cells are from different patients. (C) PBMCs from three healthy volunteers (D#1, D#2, and D#3) were cultured with 5 nM BTZ in the absence or presence of increasing concentrations of WT161 for 48 h. Cell growth inhibition was assessed by MTT assay. Data represent mean ± SD from triplicate experiments.